Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of "Buy" by Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has been given a consensus rating of "Buy" by the seven brokerages that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $11.00.

A number of research analysts have recently commented on the company. Cantor Fitzgerald initiated coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They issued an "overweight" rating and a $17.00 price objective on the stock. Leerink Partners raised their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, December 20th.

Institutional Investors Weigh In On Aquestive Therapeutics

Several large investors have recently modified their holdings of the company. Marshall Wace LLP acquired a new stake in shares of Aquestive Therapeutics during the second quarter worth about $200,000. The Manufacturers Life Insurance Company purchased a new stake in Aquestive Therapeutics during the 2nd quarter valued at approximately $76,000. Sanctuary Advisors LLC acquired a new stake in Aquestive Therapeutics during the 2nd quarter worth approximately $165,000. SG Americas Securities LLC grew its stake in shares of Aquestive Therapeutics by 58.9% in the 3rd quarter. SG Americas Securities LLC now owns 25,619 shares of the company's stock valued at $128,000 after purchasing an additional 9,496 shares during the last quarter. Finally, Creative Planning increased its holdings in shares of Aquestive Therapeutics by 39.3% in the third quarter. Creative Planning now owns 92,822 shares of the company's stock valued at $462,000 after purchasing an additional 26,185 shares during the period. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Up 14.1 %

NASDAQ AQST traded up $0.42 on Friday, hitting $3.39. 11,382,933 shares of the stock were exchanged, compared to its average volume of 1,715,561. Aquestive Therapeutics has a fifty-two week low of $2.24 and a fifty-two week high of $6.23. The company has a 50-day moving average price of $3.36 and a 200-day moving average price of $4.20. The company has a market cap of $309.10 million, a PE ratio of -7.53 and a beta of 2.67.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.